Gamma-hydroxybutyrate, the controlled medicine sodium oxybate, powerfully deepens restorative sleep and boosts next-day alertness in narcolepsy. It also releases growth hormone overnight. But the gap between an effective and a dangerous dose is small, dependence and life-threatening withdrawal are real, and no health or longevity benefit is proven outside diagnosed disorders. (Full Review)

Protocol

Starting Dose

4.5 g/night

Titrate by 1.5 g/night weekly to 6–9 g; do not exceed 9 g

Timing

At night, in bed

At least 2 hours after eating; sedation is rapid and profound

Formulation

Split or once-nightly

Immediate-release twice nightly (Xyrem/Xywav) or extended-release once (Lumryz)

Time to effect

Deep Sleep

First night

Sleep-deepening effect is immediate

Daytime Sleepiness

Several weeks

Improvement builds over weeks in narcolepsy

Full Benefit

8–12 weeks

Full daytime and cataplexy benefit in narcolepsy

Benefits

High: Deep slow-wave sleep enhancement; reduced excessive daytime sleepiness; cataplexy reduction

Medium: Nocturnal growth hormone release; fibromyalgia pain and fatigue relief; alcohol dependence and withdrawal management

Low: Improved sleep quality in healthy adults

Speculative: Antidepressant and mood effects; longevity and healthspan via deep sleep

Contraindications

Alcohol use

Concurrent sedative-hypnotics

SSADH deficiency

Untreated moderate-to-severe obstructive sleep apnea (AHI ≥15)

Significant respiratory disease

Active substance-use disorder

Key Interactions

Other CNS depressants (opioids, barbiturates, anesthetics)

Divalproex/valproate (dose reduction ~20%)

Sedating psychiatric/neurological drugs (topiramate)

Sedating antihistamines and OTC sleep aids (diphenhydramine, doxylamine)

Sedative or GABA-active supplements (high-dose GABA, valerian, kava, melatonin)

Cannabis and other recreational depressants

Risk & Side Effects

High: Dependence and withdrawal; overdose, sedation, and respiratory depression; nausea, dizziness, and common adverse effects

Medium: Bedwetting; parasomnias and confusional arousals; sodium load and blood pressure; depression and suicidality

Low: Worsening of sleep-disordered breathing

Speculative: Long-term cognitive effects

Monitoring

Marker	Target	Why
Blood pressure	<120/80 mmHg	Detects rise from the sodium load of standard formulations
Serum sodium	135–142 mmol/L	Tracks sodium intake from the standard salt formulation
Body weight / BMI	BMI 18.5–24.9; stable weight	Flags fluid retention or metabolic change
ALT (liver enzyme)	<25 U/L (men), <20 U/L (women)	Confirms adequate liver function for clearance
eGFR (kidney filtration)	>90 mL/min/1.73m²	Assesses ability to handle sodium and clear metabolites
Apnea–Hypopnea Index	<5 events/hour	Screens for sleep-disordered breathing worsened by the drug
PHQ-9 depression score	<5 (minimal)	Detects emergent or worsening depression

Cadence: Reassess at 1–2 and 4 weeks during titration, then every 3–6 months once stable

Qualitative Assessment

Morning alertness versus grogginess on waking
Daytime sleepiness and, in narcolepsy, frequency of cataplexy episodes
Sleep continuity and whether the night feels restorative
Mood, anxiety, and any low or dark thoughts
Any urge to take extra or earlier doses (an early sign of dependence)
Memory and cognitive clarity

Gamma-Hydroxybutyrate for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment